Mucosal immune regulation antiallergic powder and preparation method thereof

Abstract

The invention relates to the field of anti-allergic compositions, and discloses a mucosal immune regulation anti-allergic compound powder, which comprises the following components: metagenic powder, yeast beta-glucan, spleen protein peptide, acerola cherry powder, a probiotic composition, a prebiotic composition, Boessen berry powder, and an auxiliary material. Wherein the probiotic composition comprises lactobacillus rhamnosus GG, lactobacillus paracasei L.CASEI 431 and bifidobacterium lactis BB-12, and the probiotic composition comprises lactobacillus rhamnosus GG, lactobacillus paracasei L.CASEI 431 and bifidobacterium lactis The prebiotic composition is prepared from fructo-oligosaccharide, inulin and resistant dextrin; the auxiliary materials comprise at least two of microcrystalline cellulose, silicon dioxide and sucralose. Through coupling design of sodium alginate-pectin-chitosan three-layer embedding and a low-temperature solid-state mixing process, high-activity retention of thermosensitive components is ensured while probiotic gastric acid protection and colon targeted release are realized. Compared with a conventional double-layer embedding or high-temperature mixing process, the problems of function loss and low mucosal immune regulation efficiency are solved.

Description

Technical Field

[0001] This invention relates to the field of anti-allergy composition technology, specifically to a mucosal immune-modulating anti-allergy powder and its preparation method. Background Technology

[0002] The core pathogenesis of allergic diseases is closely related to the functional imbalance of the mucosal immune system, particularly the gut-associated lymphoid tissue (GALT). The gut is not only the site of digestion and absorption but also the largest immune organ in the human body. The integrity of its mucosal barrier, the precise regulation of immune cells (such as dendritic cells and regulatory T cells), and the defense level of secretory immunoglobulin A (sIgA) together constitute the first line of defense against allergens. Currently, dietary supplements or functional foods targeting allergies mainly focus on supplementing probiotics to regulate the gut microbiota or using inactive yeast (rich in β-glucan) for broad-based immune stimulation. For example, existing technologies (such as CN120285026A) represent the mainstream direction in this field by compounding probiotics with inactive yeast and using encapsulation and low-temperature processes to improve stability. However, these approaches are essentially still indirect and crude interventions in the gut immune environment.

[0003] The limitations of existing technologies lie in their insufficient precision and systematic regulation of mucosal immunity. Firstly, their mechanisms of action largely rely on the colonization and metabolism of probiotics in the gut, or the non-specific activation of immune cells by yeast components. They lack components capable of actively "educating" immune cells at key GALT sites (such as Pierre's nodes) and preferentially inducing immune tolerance, resulting in insufficient efficiency and directionality in immune regulation. Secondly, existing approaches focus on immune regulation itself, neglecting the direct nutritional repair and antioxidant protection urgently needed by intestinal mucosal epithelial cells under allergic stress. Indirect repair methods relying solely on short-chain fatty acids produced by prebiotic fermentation are slow and exhibit significant individual variability. Finally, existing delivery technologies (such as double-layer encapsulation) primarily address gastric acid survival, representing passive protection. Probiotics cannot actively target the core areas of intestinal immune induction, resulting in the release of large numbers of bacteria at non-target sites, reducing the efficacy and resource utilization efficiency of their immune regulation.

[0004] Therefore, there is an urgent need in this field for an innovative solution that can achieve multi-target, programmed, and precise intervention of mucosal immunity. The purpose of this invention is to provide a novel anti-allergy compound powder, innovative in that: 1) it introduces post-biotics as "educators" of mucosal immunity, pre-regulating the immune microenvironment; 2) it innovatively uses spleen protein peptides to provide direct nutrition to peripheral immune organs, strengthening the "gut-spleen axis" synergy; 3) it combines specific plant polyphenols (Bosniakberry) and vitamin C (Acerola cherry) to construct an intracellular and extracellular synergistic antioxidant network, directly protecting barrier cells; 4) it designs a three-layer intelligent encapsulation system to achieve gastric acid protection and colon-targeted delivery of probiotics. Through this systematic design, this invention aims to overcome the shortcomings of existing technologies in regulating mucosal immunity in a single, indirect, and inefficient manner, achieving a complete improvement across the entire chain from immune education, cellular nutrition, physical barrier repair to targeted delivery of active ingredients. Summary of the Invention

[0005] A mucosal immunomodulatory and anti-allergic powder, comprising the following components by weight: Post-lactic acid bacteria fermentation product (10-25 parts); 8-15 parts of yeast β-glucan (purity ≥85%); 5-12 parts of spleen protein peptide (molecular weight 800-2000 Da); Acerola cherry powder (vitamin C content ≥15%) 3-8 servings; 10-20 parts of probiotic composition; 30-45 parts of prebiotic composition; 2-5 parts of borscht powder (polyphenol content ≥25%); 4-10 parts of auxiliary materials; The probiotic composition comprises: Lactobacillus rhamnosus GG: 3.0 × 10⁻⁶ 9 -5.0×10 9 CFU / g; Lactobacillus paracasei 431: 2.0 × 10⁻⁶ 9 -4.0×10 9 CFU / g; Bifidobacterium animalis subsp. lactis BB-12: 1.5 × 10⁻⁶ 9 -3.0×10 9 CFU / g; The prebiotic composition comprises fructooligosaccharides, inulin, and resistant dextrin, wherein the mass ratio of fructooligosaccharides to inulin is 1:1.5 to 1:2.5.

[0006] The excipients include at least two of microcrystalline cellulose, silicon dioxide, and sucralose.

[0007] Preferably, the epigenetic powder contains ≥15% extracellular polysaccharide (EPS) and ≥20% peptidoglycan.

[0008] Preferably, the mass ratio of the spleen protein peptide to yeast β-glucan is 1:1.5 to 1:2.5.

[0009] Preferably, the anthocyanin content in the bosenberry powder accounts for more than 40% of the total polyphenols.

[0010] The synergistic mechanism of this invention: Postbiotics initiate mucosal immune education: Inactivated Lactococcus lactis cell wall components (peptidoglycan, lipoteichoic acid) act as ligands for pattern recognition receptors (such as NOD2, TLR2), preferentially activating dendritic cells in the Peyer's nodes of the intestine, inducing the production of IL-10 and TGF-β, and establishing a "permissive microenvironment" for subsequent probiotic colonization and immune tolerance.

[0011] Spleen protein peptides provide peripheral immune nutrition: Spleen protein peptides are rich in branched-chain amino acids and immune-active peptides, which can be absorbed by intestinal epithelial cells and transported to the spleen, promoting the proliferation of splenic lymphocytes and antibody class switching (leaning towards IgA), thereby enhancing the quality of systemic immune responses.

[0012] Yeast β-glucan forms a signal amplification loop with probiotics: β-glucan activates macrophages / dendritic cells, upregulating antigen presentation ability; activated immune cells secrete cytokines (such as IL-12), further promoting the immunomodulatory function of probiotics (especially LGG), forming a positive feedback loop.

[0013] Boysenberry polyphenols and acerola cherry vitamin C work synergistically for antioxidant effects: Anthocyanins in boysenberries can specifically inhibit the activity of mast cell NADPH oxidase, reducing the ROS required for histamine release; while vitamin C from acerola cherries regenerates intracellular glutathione, forming a dual intracellular-extracellular antioxidant barrier, stabilizing immune cell membranes and preventing over-activation.

[0014] Preparation method: Includes the following steps: S1. Multilayer encapsulation of probiotics and microencapsulation of spleen protein peptides: a. Probiotics (LGG, L.CASEI 431, BB-12) were sequentially encapsulated in three layers: sodium alginate (1.5%-2.0%, w / v), pectin (0.5%-1.0%, w / v), and chitosan (0.3%-0.8%, w / v) to form microcapsules with a particle size of 30-60 μm. The pectin layer was a pH-responsive layer that dissolved and released the bacteria at the colonic pH. b. Spleen peptides and chitosan oligosaccharides (mass ratio 5:1) were mixed and prepared into microcapsules with a particle size of 10-25 μm by iontophoresis, with an encapsulation efficiency of ≥92%; S2. Low-temperature solid-state mixing: The postbiotic powder, yeast β-glucan, acerola cherry powder, bosunberry powder, prebiotic composition and excipients were mixed at 10-20 rpm for 15-20 minutes under an inert gas (nitrogen) protection environment of 0-4℃ and relative humidity <10%; then the probiotic microcapsules and spleen protein peptide microcapsules prepared by S1 were added, and the mixture was continued to be mixed for 5-10 minutes to ensure the integrity of the microcapsule structure. S3. Repackaging and Stabilization: The mixed powder was packaged into aluminum foil composite bags (PET / AL / PE) under the condition that Aw≤0.20, and filled with 99.95% high-purity nitrogen to make the residual oxygen content in the bag ≤0.3%, and then heat-sealed. Preferably, in step S1a, the pectin is low-methoxyl pectin (esterification degree < 50%), and its mass ratio with sodium alginate is 1:3-1:5; Preferably, in step S1a, the survival rate of the encapsulated probiotics in simulated gastric fluid (pH 2.0, 2h) is ≥90%, and the release rate in simulated intestinal fluid is ≥85%. Preferably, in step S2, the inner wall of the mixing equipment is coated with a polytetrafluoroethylene (PTFE) coating to reduce electrostatic adsorption and thermal accumulation; The beneficial effects of this invention are: Pioneering a mucosal immune "education-response" linkage model: By pre-establishing an immune tolerance microenvironment through postbiotics, the efficiency of subsequent probiotic immunomodulatory effects is enhanced (measured by the proportion of Treg cells).

[0015] Achieving nutritional and immune regulation of the gut-spleen axis: Innovatively introducing spleen protein peptides to provide direct nutritional support to peripheral immune organs, increase sIgA levels, and strengthen the first line of defense of the mucosa.

[0016] Establish a multi-level oxidative stress inhibition network: Bosniak polyphenols (cell membrane targeted) and acerola cherry vitamin C (intracellular targeted) work synergistically to reduce oxidative stress markers (MDA) in an allergy model.

[0017] Develop intelligent multi-layer encapsulation and low-temperature solid-state process: Three-layer encapsulation ensures gastric acid protection and colon-targeted release of probiotics; low-temperature solid-state mixing completely avoids degradation of heat-sensitive components, with a vitamin C retention rate of ≥95%, while the powder repose angle is ≤33°, with excellent flowability, suitable for high-speed dispensing. Attached Figure Description

[0018] Figure 1 This is a schematic diagram of the process flow for the preparation method of the present invention.

[0019] Figure 2 This is a schematic diagram of the structure of the probiotic three-layer encapsulated microcapsule of the present invention.

[0020] The names of the components shown in the diagram are as follows: exist Figure 2 In the diagram, 201 represents the core probiotic composition; 202 represents the inner layer sodium alginate; 203 represents the middle layer pectin; and 204 represents the outer layer chitosan. Detailed Implementation

[0021] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention. Test methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the respective manufacturers.

[0022] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in this invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by those skilled in the art. In addition to the specific methods, apparatus, and materials used in the embodiments, based on the knowledge of those skilled in the art and the description of this invention, any prior art methods, apparatus, and materials similar to or identical to those described in the embodiments of this invention may be used to implement this invention.

[0023] Unless otherwise stated, the test methods, detection methods and preparation methods disclosed in this invention all adopt conventional techniques in this technical field.

[0024] Example 1 Formula (parts by weight): Post-Epibiotic Powder (EPS content 18%): 20 parts; Yeast β-glucan (90% purity): 10 parts; Spleen peptide (molecular weight 1500 Da): 8 parts; Acerola cherry powder (18% Vitamin C): 5 servings; Probiotic composition: 15 parts; (LGG: 4.0×10) 9 CFU / g; L.CASEI 431: 3.0×10 9 CFU / g; BB-12: 2.0×10 9 CFU / g); Prebiotic composition (fructooligosaccharides:inulin = 1:2): 38 parts; Boysenberry powder (28% polyphenols, 45% anthocyanins): 3 servings; Excipients (microcrystalline cellulose: silica = 3:1): 6 parts; preparation: The probiotics were encapsulated in a three-layer structure of sodium alginate (1.8%), pectin (0.8%), and chitosan (0.5%), with an average microcapsule size of 45 μm. Microcapsules were prepared from spleen protein peptides and chitosan oligosaccharides, with an encapsulation efficiency of 93.5%. All solid raw materials (except microcapsules) were mixed at 15 rpm for 18 minutes at 2°C under nitrogen atmosphere. Add probiotic microcapsules and spleen protein peptide microcapsules, mix at 10 rpm for 8 minutes; The water activity of the powder was reduced to 0.18, and it was nitrogen-filled (99.97%) and packaged in aluminum foil bags with a residual oxygen content of 0.25%.

[0025] Example 2 Differences from Example 1: The amount of post-natal vitamin powder has been increased to 25 parts (EPS content ≥20%). The amount of yeast β-glucan was increased to 12 parts (1 part of α-glucan from shiitake mushrooms was added for compounding). The total live bacteria count of probiotics increased by 20%; During preparation, the bosunberry extract was encapsulated in maltodextrin wall material using a freeze-drying method, and then mixed to further improve the stability of polyphenols.

[0026] Example 3 Differences from Example 1: The amount of spleen protein peptide was increased to 10 parts, and an additional 2 parts of glutamine were added; Five additional parts of stachyose have been added to the prebiotic composition to rapidly promote the growth of Bifidobacteria; In the encapsulation process, a small amount of Pierre knot targeting peptide (CSKSSDYQC) is coupled to the outer layer of chitosan to enhance intestinal targeting. After mixing, a fluidized bed low-temperature coating is used to further control moisture absorption.

[0027] Comparative Example 1 (corresponding to Example 1, without a postgene) The post-biotic powder was removed from the formula and replaced with an equal amount of maltodextrin.

[0028] Comparative Example 2 (corresponding to Example 1, spleen-free protein peptide) The spleen peptide and its microcapsules are removed from the formula, and no substitutes are added.

[0029] Comparative Example 3 (corresponding to Example 1, single-layer embedding) The probiotics are encapsulated using only a sodium alginate-chitosan double layer, with the pectin layer removed.

[0030] Comparative Example 4 (corresponding to Example 1, high-temperature mixing) The mixing step was carried out in ambient air at 25°C and 30% relative humidity, with the speed increased to 40 rpm.

[0031] Performance Testing and Results Analysis Testing standards: Viable bacteria count (CFU): The method specified in GB 4789.35-2016 National Food Safety Standard - Microbiological Examination of Food - Examination of Lactic Acid Bacteria or similar national standards / pharmacographies should be adopted.

[0032] Molecular weight determination: Describe the method for determining the molecular weight (800-2000 Da) of spleen protein peptides, such as gel permeation chromatography (GPC), and indicate information such as column type, mobile phase, and standards.

[0033] Content determination: Vitamin C: High performance liquid chromatography (HPLC) as specified in GB 5009.86-2025 National Food Safety Standard for the Determination of Ascorbic Acid in Food can be used, rather than the "iodometric method" mentioned in the text.

[0034] Total polyphenols: The Folin-Ciocalteu method is the recognized standard, and the standard used (such as gallic acid) and the detection wavelength must be specified.

[0035] Anthocyanins: The method for determining the anthocyanin content of bosenberry should be specified, such as the pH differential method.

[0036] Simulated gastrointestinal fluid experiments: The formulations of "simulated gastric fluid" and "simulated intestinal fluid" must be clearly defined, referring to the relevant provisions regarding "dissolution" or "enteric-coated preparations" in the Chinese Pharmacopoeia or USP. For example, simulated gastric fluid can be 0.2% NaCl, adjusted to pH 2.0 with HCl; simulated intestinal fluid can be phosphate buffer solution with pH 6.8.

[0037] Water activity (Aw): It should be noted that a water activity meter was used for the measurement and that it was performed at a specific temperature (e.g., 25°C).

[0038] Powder properties: The determination of angle of repose, Karl ellipse index and bulk density should refer to the "Determination of Powder Flowability" under item 0991 of the Chinese Pharmacopoeia.

[0039] Experiment 1: Comprehensive Verification of Active Ingredient Stability and Delivery Efficiency Experimental Design and Procedure Sample grouping: Example group: Take 10g of each of the finished powders from Example 1 (basic type), Example 2 (highly active type), and Example 3 (fast-acting type).

[0040] Comparative example group: Comparative Example 1: Corresponding to Example 1, but with the post-biotic powder removed from the formula.

[0041] Comparative Example 2: Corresponding to Example 1, the spleen protein peptide and its microcapsules were removed from the formulation.

[0042] Comparative Example 3: Corresponding to Example 1, the probiotics were encapsulated in a sodium alginate-chitosan double layer, and the pectin layer was removed.

[0043] Comparative Example 4: Corresponding to Example 1, the mixing step was carried out in ambient air at 25°C and 30% relative humidity, and the rotation speed was increased to 40 rpm.

[0044] Comparative Example 5: Corresponding to Example 3, the nitrogen purity was adjusted to 99.5% (residual oxygen content of about 1.5%).

[0045] Simulated gastrointestinal fluid delivery and stability test: Gastric acid tolerance: Each sample was mixed with simulated gastric juice (pH 2.0, containing 0.3% pepsin) at a ratio of 1:10, shaken at 37°C (150 rpm) for 2 hours, centrifuged, and the precipitate was collected to determine the number of viable bacteria and calculate the gastric acid survival rate.

[0046] Intestinal release rate: The precipitate after gastric treatment was resuspended in simulated intestinal fluid (pH 6.8, containing 0.1% pancreatic enzymes), and shaken for 4 hours. The number of released viable bacteria was detected, and the intestinal release rate was calculated.

[0047] Accelerated oxidation stability: The powder was placed in a constant temperature and humidity chamber at 40℃ / 75% RH for 30 days. The vitamin C content (iodometric method) and the total polyphenol content of bosunberry (Folin-Ciocalteu method) were measured on days 0 and 30, and the retention rate was calculated.

[0048] Table 1 shows the test results for each embodiment. Table 2 shows the results of the comparative tests for each item. Gastric acid survival rate and intestinal release rate: The experimental group was significantly better than Comparative Example 3. The core reason lies in the sodium alginate-pectin-chitosan three-layer encapsulation structure used in this invention. The pectin middle layer, as a pH-responsive layer, enhances the overall mechanical strength and compactness of the microcapsules in gastric juice; it dissolves in the neutral environment of the intestine, achieving targeted and orderly release into the colon. Comparative Example 3 (only double-layer encapsulation) lacks this buffer and intelligent responsive layer, and its structure is easily damaged under gastric acid shearing, resulting in a significant decrease in survival rate and release rate.

[0049] Stability of heat-sensitive components (vitamin C and polyphenols): The example group was significantly better than Comparative Example 4 and Comparative Example 5.

[0050] Comparative Example 4 (High-Temperature Mixing): Heat buildup occurred during the mixing process, which destroyed the crystal structure of vitamin C in acerola cherry powder and the active conformation of bosunberry polyphenols, resulting in extremely low retention rate after accelerated experiments.

[0051] Comparative Example 5 (low-purity nitrogen filling): Due to the high residual oxygen content in the packaging, a continuous oxidation chain reaction was triggered, which led to the rapid consumption of easily oxidized vitamin C and polyphenols.

[0052] The example group avoided heat damage by using low-temperature solid mixing at 0-4℃, and controlled residual oxygen to ≤0.3% by using ≥99.95% high-purity nitrogen filling and aluminum foil bag packaging, thus ensuring the long-term stability of heat-sensitive and oxidation-sensitive components from both the process and packaging ends.

[0053] Anthocyanin stability analysis: The anthocyanin retention rate in the example groups (85.7%-90.5%) was consistent with the trend of the total polyphenol retention rate but slightly lower. This is consistent with the characteristics of anthocyanins as a subclass of polyphenols with a more complex structure and greater sensitivity to light, heat, and oxygen. The anthocyanin retention rate in Comparative Example 4 (high-temperature mixing) dropped sharply to 42.7%, significantly lower than its total polyphenol retention rate (48.9%), which strongly demonstrates the abnormal sensitivity of anthocyanins to heat. The instantaneous heat accumulation caused by high-temperature mixing severely damaged the benzopyran cationic structure of anthocyanins, leading to their degradation and discoloration. This directly verifies the necessity and superiority of the 0-4℃ low-temperature solid-state mixing process of this invention for protecting such highly active and heat-sensitive phytochemicals. The anthocyanin retention rate in Comparative Example 5 (low-purity nitrogen filling) (52.3%) was also at an extremely low level. Although its thermal damage was small, the high residual oxygen in the packaging triggered continuous oxidation of the phenolic hydroxyl groups in the anthocyanin molecules, resulting in the destruction of their conjugated structure. This demonstrates that the packaging method of this invention, which uses ≥99.95% high-purity nitrogen and controls residual oxygen to ≤0.3%, is crucial for maintaining the long-term antioxidant activity of anthocyanins.

[0054] Experiment 2: Validation of the synergistic effect between mucosal immune regulation and anti-allergic function Experimental Design and Procedure Sample grouping: Examples 1-3, Comparative Examples 1-5 (preparing their aqueous extracts or directly using powder suspensions).

[0055] In vitro immune regulation assessment: Dendritic cells (DCs) isolated from mouse Pierre nodes were co-cultured with each sample (final concentration 1 mg / mL) for 24 hours; Flow cytometry was used to detect the expression ratios of CD86 (an activation marker) on the surface of dendritic cells (DCs) and IL-10 (a tolerance marker) intracellularly.

[0056] Intestinal barrier repair function assessment (Caco-2 cell model): Establish Caco-2 cell monolayer (TEER value ≥ 300 Ω·cm) 2 Add the sample (0.5 mg / mL) and treat for 48 hours; The rate of change in transepithelial electrical resistance (TEER) was measured, and the expression level of the tight junction protein ZO-1 was quantified by immunofluorescence.

[0057] In vivo anti-allergic effect (mouse OVA allergy model): BALB / c mice were sensitized with ovalbumin (OVA) and administered each sample (50 mg / kg) by gavage daily for 14 days. The OVA-specific IgE titer and histamine concentration in serum were measured, and the inhibition rate was calculated. Small intestinal flushing fluid was collected, and the content of secretory immunoglobulin A (sIgA) was measured.

[0058] Table 3 shows the test results of the synergistic verification test of mucosal immune modulation and anti-allergic function in the examples and comparative examples. Immunomodulation (IL-10+ DCs): The results in the Example group were significantly higher than those in Comparative Example 1. This directly confirms the core "immunoeducation" role of the metabiotic (inactivated Lactococcus lactis). Its cell wall components (peptidoglycan) are preferentially recognized by Pierre's knot DCs, inducing an immune tolerance phenotype (high IL-10). In Comparative Example 1, the metabiotic was removed, thus losing this initiation step, and immune regulation began in a non-tolerant state.

[0059] Intestinal barrier repair (ZO-1): The example group was significantly superior to Comparative Example 2. Spleen peptides, as direct nutrients and repair substrates for intestinal epithelial cells, can rapidly activate cell proliferation and tight junction protein synthesis pathways. Comparative Example 2 removed this component and relied solely on indirect acid production from prebiotic fermentation for repair, which was slow and inefficient.

[0060] Anti-allergic effect (IgE inhibition and sIgA enhancement): The example group showed the best synergistic effect.

[0061] Comparative Example 3 (single-layer encapsulation) failed to fully utilize its immunomodulatory function due to low probiotic delivery efficiency, resulting in both low IgE inhibition rate and low sIgA enhancement rate.

[0062] The example group achieved comprehensive suppression of allergic reactions and enhancement of mucosal immunity through multiple synergistic effects, including efficient delivery of probiotics via triple encapsulation, post-biotic tolerance initiation, spleen protein peptide support for systemic immunity, and polyphenol antioxidant stabilization of immune cells.

[0063] Experiment 3: Verification of Powder Properties and Applicability to Industrial Production Experimental Design and Procedure Sample grouping: Examples 1-3, Comparative Examples 1-5.

[0064] Basic Powder Properties Test: Angle of repose and Karl index: determined according to pharmacopoeia methods to assess flowability.

[0065] Bulk density and tapped density: Calculate the Hausner ratio to assess filling properties and compressibility.

[0066] Subpackaging process simulation test: Using a laboratory-simulated nitrogen-filling dispensing equipment, the target speed was set at 100 bags / minute.

[0067] Record the actual dispensing speed that can be operated stably, and randomly sample and test the filling volume difference (RSD%) and sealing pass rate.

[0068] Storage stability acceleration test: The powder was stored at 40℃ / 75% RH for 7 days.

[0069] The agglomeration situation was observed and recorded daily. On the 7th day, the powder was passed through a 20-mesh sieve and the agglomeration rate was calculated. At the same time, the change in the brightness L* value of the powder was measured using a colorimeter to assess the degree of browning. Powder flowability (angle of repose, Karl Fischer index): Example group showed the best flowability, while Comparative Examples 2, 3, and 4 showed poor flowability. Comparative Example 2, due to the removal of the smooth-surfaced spleen peptide microcapsules, lost the "ball bearing" effect that improved particle flowability. The monolayer-encapsulated microcapsules in Comparative Example 3 may have a stickier surface or be prone to generating small fragments, increasing internal friction. The high-temperature mixing in Comparative Example 4 may have caused some low-melting-point excipients (such as sorbitol) to slightly soften or absorb moisture, making the particle surface sticky and significantly deteriorating flowability. Dispensing performance: Examples 1 and 3 showed good dispensing speed and filling accuracy, meeting the requirements for high-speed industrial dispensing (RSD < 3%). Comparative Example 4, due to its poor flowability, resulted in slow dispensing speed and large fluctuations in filling volume. Storage agglomeration: The agglomeration rate in the Example group was extremely low (< 1.1%), mainly due to strict water activity control (Aw ≤ 0.20) and a powder structure with good flowability. Although Comparative Example 5 had good flowability, its low nitrogen purity (99.5%) meant that residual moisture and oxygen could still cause localized hygroscopicity and a slight Maillard reaction under high temperature and humidity, resulting in a significantly increased agglomeration rate (3.0%).

[0070] Finally, it should be noted that the above embodiments are used to illustrate the technical solutions of the present invention and not to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A mucosal immune-modulating and anti-allergic powder, characterized in that, The product comprises the following components by weight: 10-25 parts postbiotic powder, 8-15 parts yeast β-glucan, 5-12 parts spleen peptide, 3-8 parts acerola cherry powder, 10-20 parts probiotic composition, 30-45 parts prebiotic composition, 2-5 parts boysenberry powder, and 4-10 parts excipients; wherein the probiotic composition contains Lactobacillus rhamnosus GG, Lactobacillus paracasei L.CASEI 431, and Bifidobacterium lactis BB-12; and the prebiotic composition contains fructooligosaccharides, inulin, and resistant dextrin.

2. The powder according to claim 1, characterized in that: The post-biotic powder is a fermentation product of inactivated Lactococcus lactis. Its extracellular polysaccharide content is ≥15%, and its peptidoglycan content is ≥20%.

3. The powder according to claim 1, characterized in that: The spleen protein peptide has a molecular weight of 800-2000 Da, and the mass ratio of the spleen protein peptide to yeast β-glucan is 1:(1.5-2.5).

4. The powder according to claim 1, characterized in that: The mass ratio of fructooligosaccharides to inulin in the prebiotic composition is 1:(1.5-2.5).

5. A method for preparing the anti-allergy powder according to any one of claims 1-4, characterized in that, Includes the following steps: S1. Pre-treat the probiotics by sodium alginate-pectin-chitosan three-layer encapsulation, and pre-treat the spleen protein peptide by chitosan oligosaccharide microencapsulation; S2. Mix the pre-treated components with other solid components at low temperature under inert gas protection at 0-4℃; S3. Dispense and control the water activity Aw≤0.20, and use nitrogen-filled packaging.

6. The method according to claim 5, characterized in that, The process parameters for the three-layer encapsulation of probiotics in S1 include: sodium alginate solution concentration of 1.5-2.0% (w / v), pectin solution concentration of 0.5-1.0% (w / v), chitosan solution concentration of 0.3-0.8% (w / v), and the resulting microcapsule particle size of 30-60 μm.

7. The method according to claim 5, characterized in that: The encapsulation efficiency of the spleen protein peptide microencapsulation in S1 is ≥92%, and the microcapsule particle size is 10-25μm.

8. The method according to claim 5, characterized in that: The mixing process in S2 is carried out in an environment with a relative humidity of <10%, the inner wall of the mixing equipment has an antistatic coating, and the total mixing time is 20-30 minutes.

9. The method according to claim 5, characterized in that: The nitrogen used in the nitrogen-filled packaging in S3 has a purity of ≥99.95%, and the residual oxygen content inside the packaging bag is ≤0.3%.

10. The use of the anti-allergy powder according to any one of claims 1-4 in the preparation of functional foods or dietary supplements for the prevention or relief of allergic rhinitis, allergic dermatitis or food allergies.

Images